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Abstract 
Carcinoma of the urinary bladder 
Aspects of treatment, costs and follow-up routines
Ingela Berrum Svennung, Department of Urology, Institute of Clinical Sciences, the 
Sahlgrenska Academy at Göteborg University, Sahlgrenska University Hospital, Sweden 
Aims: To determine costs and factors related to the total costs of cystectomy. To study 
the results of the radiological examinations performed 7-14 days after cystectomy. To 
investigate if a single instillation of epirubicin after transurethral resection (TUR) may 
influence the time to the first recurrence and its size. To elucidate if a routine with 
reduced numbers of follow-up cystoscopies in patients with stage Ta tumour is safe. 
Patients and methods: The clinical records of 70 consecutive patients subjected to
cystectomy were studied. Costs were determined for cystectomies and 22 different factors 
possibly related to total costs were analysed. The clinical records for a total number of 
200 consecutive cystectomy patients were analysed for the results of the postoperative 
urography. A total number of 404 patients in 13 hospitals were randomised to either one 
instillation of 50 mg epirubicin or placebo within 6 hours after TUR. We included  
138 patients with low-grade tumours who had a negative 4–month cystoscopy in a 
prospective observational study. The size and number of subsequent recurrences were 
determined.
Results and conclusions: The total costs (median) for cystectomy was 189,479 SEK. 
Room and Board was the most expensive single item. In the multivariate analysis high 
peroperative blood loss was the most important factor associated with high total hospital 
costs. Not a single patient out of 170 had urinary leakage or a significant stricture 
visualised at the postoperative urography. It can be concluded that a postoperative 
urography is unnecessary in patients with a normal postoperative course. Seventy-nine 
(51.0%) out of 155 evaluable patients in the epirubicin group had a recurrence as 
compared to 95 (62.5%) out of 152 patients in the placebo group. Half of the recurrences 
were small-sized and could be fulgurated at the time of the follow-up cystoscopy. The 
clinical benefit of single instillations thus seems questionable. Patients with low-grade 
stage Ta tumours who are tumour-free at 4 months can safely follow a routine with 
cystoscopy at month 12 and 24 and almost all recurrences can be fulgurated at follow-up. 
Key words: bladder cancer, cystectomy, stents, economics, follow-up cystoscopy, single-
instillation, epirubicin, recurrence size 
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Introduction 
Cancer of the urinary bladder is the ninth most common malignant disease worldwide 
with approximately 250,000 new cases each year (Cookson 2004). It is the fifth most 
common malignancy in Europe and the fourth in the United States (American Cancer 
Society, 2007). Bladder cancer is one of the most prevalent cancer diseases as a result of 
the long mean survival time among bladder cancer patients. Median age in Sweden at 
diagnosis is 72 years. More than 50% of all tumours are at diagnosis non-invasive (stage 
Ta), whereas approximately 40% of primary tumours are invasive, i.e invading sub-
epithelial connective tissue or muscle (stage T1-T4) (Larsson 2003). Treatment is 
completely different for these groups.  The management of each individual patient 
depends on many different factors, most important is the stage and grade of the disease 
but the physical condition and mental status as well as patients preferences are also 
important. The total cost per patient is the highest of all cancers due to the long average 
survival of the bladder cancer patient and the need for lifelong routine monitoring and 
treatment (Botteman 2003). 
This thesis has its focus on bladder cancer follow-up routines, treatment and economic 
aspects of the disease. 
Carcinoma of the urinary bladder 
Epidemiology, aetiology and pathology 
Cancer in the urinary bladder has a worldwide variation in incidence. The incidence rate 
of cancer is defined as the number of new cases diagnosed per 100,000 persons per year. 
The incidence rate of bladder cancer in the western world is 10-30 new cases/100,000 
persons.  Bladder cancer is uncommon in Asia, but has a very high incidence in for 
example Egypt. The highest incidence internationally is found in Italy for men and for 
women in New Orleans (Napalkov 1997). Incidence rates are generally higher in the 
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developed countries, with exception for earlier described countries with endemic 
schistosomiasis. In Sweden 2,000 new cases are diagnosed yearly. Urinary bladder cancer 
is the fifth most common malignancy disease in Sweden (Socialstyrelsen: 
Epidemiologiskt centrum). Bladder cancer is after prostate cancer the most common 
urologic cancer in Sweden. Bladder cancer has a great variation in incidence due to 
gender and race. The disease is between two to five times more common in men than in 
women. Race also influences the incidence rate with a factor of 1.5-2. It is most common 
in white men and unusual in black women. 
                   Transitional cell carcinomas comprise more than 90% of bladder cancers in western 
countries. In Sweden, 97% of all urinary bladder cancers are transitional cell carcinomas 
(Nationellt kvalitetsregister för blåscancer – diagnosår 2005). A few per cent are 
squamous cell carcinomas and adenocarcinomas. Small cell carcinomas and lymphomas 
are occasionally seen while malignant melanomas are distinctly rare. The prevalence of 
squamous cell carcinomas is considerably higher in Egypt and the Middle East, where 
infection by Schistosoma Haematobium is endemic.  
The mortality in Sweden in bladder cancer is approximately 600 cases a year. The 
number of bladder cancer deaths is unchanged despite an increase in the number of new 
bladder cancer cases in Sweden during the last decades.  
10
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                 Figure 1   
Incidence 1961-2003
Bladder cancer 
Mortality 1961-2003 
Bladder cancer 
Figure 2 
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Risk factors for bladder cancer are mostly exogenous. Smoking is a major, well-
established and avoidable risk factor for bladder cancer. Smoking increases the risk 
fourfold compared to persons who have never smoked (Steineck 1970).  The latency 
period is approximately 20-30 years. Smoking accounts for one-third to half of bladder 
cancers diagnosed among men and one-quarter of those among women. Smoking black 
tobacco appears to result in a higher risk than smoking blond tobacco. Other risk factors 
for bladder cancer are previous pelvic radiation, previous systemic chemotherapy, local 
long-term irritating factors such as cystolithiasis and chronic catheter. Workers in the 
rubber and chemical industry as well as in the steel, iron and aluminium industry also 
have an increased risk. 
Biology 
One theory is that carcinogens in urine cause bladder cancer due to damage of the DNA in 
the urothelium. The main change in grade 1 tumours seems to be in chromosome 9. These 
tumours have a high risk of recurrence but a low risk of progression. 
Grade 2-3 tumours have a disturbance in the p53-synthesis, which is regulated from 
chromosome 17 (Malmström 2006). These theories support the clinical observation that 
bladder cancer is a number of different diseases with different grade and infiltrative
properties. 
The incidence of subsequent upper tract tumours is only 3-4% in patients with a primary 
bladder cancer. On the other hand, patients with primary tumours in the renal pelvis and 
ureter run a 40% risk of a subsequent bladder cancer. This is indirect evidence for the 
theory that urothelial cancer cells spread in a distal direction with the flow of urine. 
12
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Symptom and signs 
The most common presenting symptom is painless haematuria episodes, which occurs in 
about 81% of bladder cancer patients. Other common symptoms are voiding problems, 
urinary tract infections and abdominal pain (Boman 2002). The patient can also have 
anaemia and sterile pyuria. 
Primary investigation 
The first step in the diagnosis is cystoscopy, often with urinary or bladder wash cytology. 
Cytology has a high specificity (97-100%) but varies considerably in sensitivity, which is 
high (90-95%) in large-sized high-grade tumours but low (20-30%) in small-sized low-
grade tumours. Histopathological material from the tumour is obtained by means of a 
transurethral resection of the bladder (TURB). All patients with suspected bladder cancer 
undergo at least one TURB, with bimanual palpation, which provides important 
prognostic information (Wijkström 1984). 
The purpose of TURB can be a complete removal of all visible tumour or just a way to 
get tissue for diagnosis, depending on how advanced the tumour is. It also gives 
information about the stage and grade. TURB should be in two fractions, superficial and 
deep to make it easier for the pathologist to determine the depth of infiltration.  
A physical examination and a careful patient history are natural parts of the primary 
investigation for evaluation of the presence and degree of any comorbidity. 
Normal urinary bladder 
The normal urothelium is three to seven cell layers thick and has contact with urine at its 
surface. The urothelium rests on the basal membrane of the lamina propria. This 
membrane borders on the lamina propria, or the sub-epithelial connective tissue, which 
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includes some smooth muscle fibres. The detrusor muscle layer is organised in a criss-
cross way, like a basket, so each fibre runs from the outer to the inner layer and back 
again. Outside this layer is abundant fat in which multiple plexa with large veins are 
found.
Transurethral resection of the bladder 
This type of surgery is for the first time in almost all patients performed at the operation 
theatre since most primary tumours are larger than 10 mm in diameter.  Patients are under 
general or spinal anaesthesia during surgery. TUR of smaller tumours can be performed 
as day-care surgery. A lubricating jelly with local anaesthesia in the urethra is always 
used before introducing the resectoscope into the urinary bladder. The resectoscope has a 
loop which is 6.5 millimeters wide (Fig. 3). The suspected tumour is cut away with the 
loop. Tumour tissue is removed and sent for histopathological examination in the 
Department of Pathology. Smaller recurrent tumours can be fulgurated and/or biopsied in 
the office under local anaesthesia. 
Figure 3. TURB 
Classification - tumour grading 
The biological behaviour of a tumour differs from grade to grade. Consequently, it is of 
utmost importance to know the tumour grade since treatment and prognosis vary 
depending on the grade. 
Bladderwall 
Resektoskop 
Tumour 
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At the present time (2007) in Sweden the WHO classification from 1999 is used although 
there is a later version from 2004. This classification system (WHO 1999) consists of 
three different grades of cancer and papillary urothelial neoplasm of low malignant 
potential (PUNLMP). PUNLMP is not a cancer but has an inherent low potential for later 
development of a truly malignant disease.  It corresponds to the most benign forms of 
grade 1 tumours in the WHO 1973 classification system (Busch 2002). Actually, the 1973 
WHO system is still the most used grading system worldwide. It also has a three-tier 
grading system but only grades one and three are defined. Grade 2 was not clearly 
outlined which is the main critique against the WHO 1973 classification.  Many 
pathologists were tempted to use grade 2 too often, which was a great problem for 
urologists, since some of these grade 2 tumours were almost grade 3 tumours and others 
were almost grade 1 tumours (Holmäng 2000). Another classification system was 
suggested by Bergkvist and Moberger (Bergkvist 1965). This system was modified by 
Malmström and co-workers in 1987 (Malmström 1987). Grade 2 tumours were divided in 
2 subgroups (2A and 2B) between which there is a sharp limit which has clinical 
importance. WHO 1999 is similar to the modified Bergkvist system. WHO 2004 is the 
most recent grading system, which is recommended in the EAU guidelines, but not used 
in Sweden. 
Table 1. Comparisons of different grading systems 
WHO 1973     Modified.Bergkvist 1987    WHO/ISUP 1998           WHO 1999
       I                        I                                  PUNLMP                        LMP 
      II                      IIA                               Low-grade                        I 
      II                      IIB                               High-grade                      II 
      III                     III                                High-grade                      III 
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Staging of bladder tumours is performed according to the TNM classification from 2002. 
Table 2. TNM classification 2002 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ (flat tumour) 
T1 Tumour invades sub-epithelial connective tissue 
T2 Tumour invades muscle  
T2a tumour invades superficial muscle (inner half) 
T2b tumour invades deep muscle (outer half) 
T3 Tumour invades perivesical tissue 
T3a microscopically 
T3b macroscopically (extra vesical mass) 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, 
abdominal wall 
T4a Tumour invades prostate, uterus, or vagina 
T4b Tumour invades pelvic wall or abdominal wall 
Figure 4. TNM 2002 
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The Tumour, Node, Metastases (TNM) 2002 is widely accepted, also in Sweden. The 
prefix T means clinical stage which is an assessment at the time of cystoscopy combined 
with results from radiological examinations.  When information on the histopathological 
information is included it is termed “pT”. The majority of bladder cancers, over 50%, are 
Ta tumours. It is important to separate all infiltrative tumours from the Ta group, since it 
is a different type of disease. The term superficial bladder tumour includes Ta, Tis and T1 
tumours but is no longer recommended. The reason is that it comprises tumours with 
widely varying biological potential (Murphy 2000, Soloway 2002). For planning the 
follow-up it is a must to know stage and grade of the tumour. 
Stage and initial treatment 
The prognosis of bladder cancer depends on both stage and grade. The goal with staging 
is to get more information about the tumour in order to give appropriate treatment leading 
to an optimal prognosis. 
Flat tumours – carcinoma in situ 
It is an invisible disease since most of the diseased areas in the bladder cannot be seen. 
Actually, carcinoma in situ cannot be seen at all. What we see are red oedematous areas 
that are the result of inflammation in the lamina propria underlying the carcinoma in situ. 
This disease is almost always multifocal and incurable with TUR only, since all involved 
areas cannot be identified. There are two different types of CIS. Primary, which is CIS 
without any earlier or coexistent tumour. This type comprises 1-2% of all newly 
diagnosed bladder carcinomas. Secondary Tis, which is CIS with a concomitant or earlier 
papillary tumour. This type is the most common kind of CIS.
CIS has a high progression rate and all patients with CIS should have BCG treatment as 
soon as possible. BCG treatment results in approximately 80% complete response 
determined at the first follow-up cystoscopy but after five years only approximately 50% 
are still tumour-free. Radical cystectomy is the preferred treatment when intravesical 
measures fail. 
17
- 18 - 
Stage Ta 
Stage Ta is the most common form of bladder cancer. Ta bladder tumours grow in the 
mucosa in a papillary and non-invasive way. Such tumours comprise 49% of all newly 
diagnosed tumours in Sweden (Nationellt kvalitetsregister för blåscancer – diagnosår 
2005). The recurrence rate for this group is high, 50-70%, but the progression rate is low, 
between 2 and 10%.
PUNLMP are always non-invasive and comprise approximately 10-15% of all newly 
diagnosed tumours. They have an excellent prognosis with minimal or no risk at all of 
progression. The risk of recurrence is 35% during the first five years (Holmäng 1999).  
Approximately 33% of the patients have Stage Ta Grade 1 tumours at initial diagnosis. 
Stage progression occurs but no more than 5% during five years of follow-up. Solitary Ta 
grade 1 tumours require no adjuvant treatment apart from possibly a single instillation of 
a cytostatic agent.  
Stage Ta Grade 2 constitutes 10-20% of all newly diagnosed tumours. Progression in this 
group of high-grade tumours is higher, up to 20% in one report (Holmäng 2001). 
Although other authors have found a much lower progression rate it seems appropriate to 
have respect for these tumours and have a different treatment regimen and follow-up 
routine than what is the case for grade 1 tumours. There are no studies which can guide us 
in this matter but the best way may be to treat multifocal and/or large-sized TaG2 tumours 
like TaG3 tumours. Taking into account the high recurrence rate and the progression rate 
it may well be the case that these tumours should be liberally treated with intravesical 
BCG or intravesical chemotherapy.  
Stage Ta G3 is not so common and represents only 3% of all newly diagnosed tumours. 
The progression rate of grade 3 tumours varies from report to report ranging from 0% to 
45%.
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Figure 5. % progression in Ta tumours
Stage T1 
Twenty per cent of all bladder carcinomas infiltrate the lamina propria but not deeper
already at initial diagnosis. Thus, they penetrate the basal membrane and invade a 
subepithelial layer of connective tissue. Most of the T1 tumours are grade 3. Stage T1 can 
be sub-staged into three levels of invasion, T1a, T1b and T1c. T1a tumours are tumours 
which infiltrate into the superficial part of the lamina propria. T1b tumours infiltrate 
deeper into the layer where the large vessels and muscle bundles are located. T1c tumours 
infiltrate even deeper and almost reach the muscularis propria. T1b and T1c are 
sometimes combined and termed T1b.  T1a is usually termed superficial and T1b deep 
lamina propria invasion. The depth of invasion is an important prognostic factor for 
progression. Re-resection is recommended for all T1 tumours to ascertain that the patient 
has been correctly staged and also to improve radicality.  
BCG is recommended in T1 grade 2 and 3 without solid tumour pattern and vascular 
invasion. Immediate cystectomy is the choice of treatment in T1 grade 2 and 3 with solid 
tumour pattern and/or vascular invasion (Andius 2006). 
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Stage 2-4 and metastatic disease
T2 denotes an infiltration into the muscle layer and is substaged into two levels, A and B, 
depending on whether the depth of infiltration is superficial or deep into the muscle layer. 
Stage 3 is also subdivided into two levels, A and B, depending on micro- or 
macroinfiltration to the perivesical tissue. Approximately one third of the patients with 
newly diagnosed disease are in stages T2-3-4. Radical cystectomy is recommended in T2, 
T3, T4a, No-Nx, M0. 
Sometimes a cystectomy can be performed in more advanced cases in order to get 
palliation from severe local symptoms such as recurrent bleeding. 
Intravesical chemo- and immunotherapy – history and management 
Intravesical instillations were first described as early as in 1903. Instillations of cytostatics 
have been used in the management of bladder cancer since the 1960s. A considerable 
number of substances have been tested (Table 3).  
Table 3. 
Instillation agent history
• 1903 Silver nitrate
• 1919 Triklorättiksyra
• 1948 Podofyllin
• 1961 Thiotepa
• 1965 Actinomycin C
• 1965 5-Fluorouracil
• 1966 Mannitol myleran
• 1966 Metotrexate
• 1967 Mitomycin C
• 1973 Epodyl
• 1976 BCG
• 1977 Adriamycin
• 1986 Epirubicin
• 1990 Interferon
• 1997 Valrubicin
Malmström PU:  Crit Reviews Oncol/Hematol 2002
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At the present time (2007) the following substances are the most used: Thiotepa,  
Adriamycin, Epirubicin, Mitomycin C and BCG. 
The majority of patients with stage Ta/T1 bladder tumours can be given instillations
prophylactically and/or treated with instillation therapy. The duration time for instillation 
therapy is as a rule one to two hours. The optimal effect is achieved when the patient 
changes position every fifteen minutes so that all parts of the bladder can come into 
contact with the solution. Chemotherapy instillations can be given in two different ways, 
one single instillation immediately after TURB or additional courses of instillations 
during four to eight weeks. It is recommended that patients with no prior intravesical 
therapy are given a single instillation of a cytostatic drug after endoscopic removal of 
low-grade Ta bladder cancers. Intravesical instillation of BCG or mitomycin C is 
recommended for CIS and after endoscopic removal of T1 and high grade Ta tumours. On 
the other hand, chemotherapy may be helpful in BCG failures (Malmström 1998). 
BCG  
BCG immunotherapy is at present the most effective intravesical agent for treatment and 
prophylaxis of high-grade bladder cancer. The exact mechanism is unknown. The 
treatment can be given a couple of weeks after resection, depending on the size of the 
resection surface. Immunotherapy is the first-line treatment for CIS. BCG is the only drug 
with at least some effect against progression. Other treatment indications are T1 disease 
and multifocal or recurrent Ta tumours. The traditional treatment schedule is one 
instillation once every week for 6 weeks with additional instillations in many cases. 
Mitomycin C
Mitomycin C is an antitumour antibiotic. It has a low molecular weight and is usually 
minimally absorbed when given intravesically. There is no standard dose, and it may vary 
from 20 to 60 mg per instillation. Chemical cystitis is the most common side-effect but it 
will disappear after cessation of therapy. 
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Epirubicin 
Epirubicin is a cytotoxic antibiotic. It has an antitumoural effect by binding to DNA 
resulting in an inhibition of the enzyme system which is essential for the transcription and 
replication of DNA.
Epirubicin is usually administered in a dose of 30–80 mg diluted in saline.
The only significant side-effect of epirubicin appears to be drug-induced cystitis. 
Single-shot instillation 
An unwanted effect of TURB is that cancer cells are freed from the tumour, float around 
in the bladder and may implant in the TUR wound or other injured urothelial surfaces. 
Instilled cytotoxic agents will mostly exert their effect on tumour cells since the normal 
urothelium has a low mitosis activity. This will hopefully minimise implantation and 
further growth. 
Popart et al. showed that a single instillation of epirubicin had a significant effect on 
marker lesions with acceptable toxicity (Popart 1985). A number of randomiced studies 
have been performed which show that a single instillation of a cytotoxic drug, mainly 
epirubicin and mitomycin, will reduce the number of subsequent recurrences (Burnard 
1976, Abrams 1981, Zincke 1993, Oosterlinck 1993, Bouffioux 1995, Tolley 1996, Ali-
El-Dein 1997, Solsona 1999, Rajala 2002 and Okamura 2002). Single-shot instillation is 
recommended for all Ta and T1 tumours in the European Guidelines since 2002. It is 
known that a single postoperative instillation of epirubicin and mitomycin result in a 
lower recurrence rate, but there is a lack of knowledge in some aspects, for example the 
size of the recurrences and the costs for a single instillation treatment policy. 
Recurrences 
Up to 75% of all patients with Ta, Tis and T1 tumours will have recurrences during the 
first five years after the initial diagnosis if TUR was the only treatment. Different 
mechanisms have been suggested for the high recurrence rate. 1. Residual tumour, due to 
an incomplete resection. 2. Small-sized tumours, not visible at the time of the primary 
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resection. The tumour will be visible at follow-up. 3. Precancerous changes in the entire 
bladder urothelium “field change” result in a high recurrence rate for some tumours. 4. 
Cancer cell implantation at the site of resection. 
The temporal risk for recurrences is biphasic and is highest around month 3 and 21 
(Malmström 2003). 
Prognostic factors 
The most important prognostic factors for Ta and T1 tumours are the number of tumours, 
tumour size, prior recurrence rate, T category, presence of CIS, tumour grade and poor 
response to intravesical therapy. 
Staging tests 
  
TUR, bimanual palpation and intravenous pyelography are recommended in the EAU 
guidelines for T-staging. Ultrasonography, bone scan and CT or MRI are optional
evaluations. 
 CT abdomen provides information about the presence or absence of pelvic and para-
aortic lymphadenopathy and visceral metastases as well as bladder tumour infiltration 
depth and adherence to surrounding tissue and organs. CT should preferably be done 
before TURB for correct information. CT and MRI both have an inherent staging error, 
since their ability to identify small-sized lymph node metastases is poor. For N-staging 
the only method capable of excluding metastatic disease in lymph nodes is 
lymphadenectomy. For M-staging, chest radiographs are recommended in all patients. 
Bone scans are recommended in patients who have symptoms that suggest bone 
involvement. Ultrasound is an easy way to find out if a liver metastasis is present. 
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Radical cystectomy 
Radical cystectomy including urinary diversion is the golden standard treatment for 
muscle-invasive bladder cancer and for stage Ta/T1/Tis bladder cancer when local 
therapies have failed.
Unfortunately, not all of these patients are in a good enough physical and mental 
condition to undergo such extensive surgery as cystectomy. 
Radical cystectomy actually includes three surgical procedures: 1. Lymph node 
dissection, 2. Cystectomy and 3. Urinary diversion. 
Lymph node dissection can be performed in many ways and different authors describe 
various types of dissection. Limited lymph node dissection is an extirpation of lymphatic 
tissue in the obturator fossa which provides just a few nodes. Limited dissection can be a 
bit more extensive and include the area between the genito-femoral nerve and internal 
iliac vessel, a so called conventional pelvic dissection. Extended dissection includes all 
lymphatic tissue up to the aortic bifurcation and sometimes even up to the inferior 
mesenteric artery. There is no consensus in the way the lymph node dissection should be 
performed due to the lack of randomised studies. Cystectomy in the male patient includes 
removal of the bladder as well as the distal part of the ureter, seminal vesicles and 
prostate. The uterus, adnexa and anterior wall of the vagina should be removed in the 
female patient.
 Radical cystectomy with urinary diversion is associated with a high complication rate of 
about 20-30%. Common complications are ileus, wound rupture and infections (Rosario 
2000, Malavaud 2002, Chang 2002). The postoperative mortality is the time up to 30 days 
after surgery and is mostly a result of treatment complications. The mortality is 1-5% but 
may be even higher in some hospitals (Schoenberg 2002, Malavaud 2002). 
 The mortality is usually not significantly increased due to high age, poor physical 
condition, co-morbidity or stage. The EAU guidelines recommend that a surgical 
procedure like cystectomy should be performed in centres with good experience of the 
major types of diversion techniques. Urinary diversion can be performed in three ways; 
incontinent urinary diversion, continent urinary diversion and orthotopic neobladder 
substitution. (Fig 6-8) 
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 Ileal conduit, the incontinent alternative, is a surgical procedure which is not so 
technically difficult in comparison with the reservoirs. In the other two diversion types a 
reservoir is constructed. The orthotopic neobladder is sutured to the urethra and the 
continent pouch is connected to a stoma below the umbilicus. The Bricker conduit is the 
most common type of diversion in Sweden. Actually, it has gained increased popularity 
during recent years. In 1997, 55% of the diversions following cystectomy for bladder 
carcinoma were incontinent diversions compared to 72% in 2005 (Nationellt 
kvalitetsregister för blåscancer – diagnosår 2005). One possible explanation for this 
change is that more and more elderly patients have been operated on and a Bricker 
conduit is the preferred alternative in this group.   
Radiation therapy is an alternative to radical cystectomy but results seem to be inferior. It 
is estimated that up to 50% of patients will get recurrences within the bladder. Curative 
radiotherapy is suggested as a treatment in elderly patients who are unfit for cystectomy 
but there are actually few, if any, studies performed in this patient category which show 
any benefit of the treatment. 
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Published with permission 
from Lars Henningsohn 
Figure 6 
Figure 7
Figure 8
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Postoperative management after cystectomy with urinary diversion 
Patients who have undergone a cystectomy with urinary diversion may need an 
abundance of resources postoperatively. Most patients are in the intensive care unit during 
the first period after surgery. Epidural anaesthesia is frequently used during the first days 
for lowering the postoperative pain.
  At the present time (2007) many of the patients who undergo cystectomy are elderly and 
have one or more comorbidities and thus need more help. The length of hospital stay after 
cystectomy was reported by many authors and is at least partly related to the complexity 
of the urinary diversion. Mean postoperative hospital stay varies in different studies 
between 7 to 22.7 days (Bredin 1977, Malavaud 2002, Rosario 2000, Chang 2002). 
During the first days after surgery the fluid balance is controlled. Serum electrolytes are 
checked periodically. Most patients can start drinking small amounts the day after surgery 
if they are in such a condition that the nasogastric tube can be removed. Enteral nutrition 
starts often after the third day, since many patients have a prolonged ileus. Ureteral stents 
are considered favourable and are routinely inserted during the operation. Most patients 
undergo some form of radiological evaluation before the removal of the ureteric stents. 
Guidelines and national recommendations do not include postoperative management 
explaining why it differs from hospital to hospital. There is a lack of scientific evidence 
and studies on ureteral stents and the possible value of radiological evaluations. The 
drainage tube is left in place for some days depending on the amount of the discharge. 
Women have their vaginal pack for about one day. Antibiotic prophylaxis is routine but 
varies from department to department; from a single per-operative dose to 3 days.
Complications are common, as previously mentioned and may result in prolonged time in 
the ward. During the postoperative period specially trained nurses and stomal therapists 
help the patient to learn to care for the stoma and change the collection bags. Some 
patients need one to three weeks in a geriatric ward before returning home.  
27
- 28 - 
Costs 
Bladder cancer is one of the 10 most common malignant diseases worldwide and 
treatment costs are substantial. From a clinical and economic aspect it is important to 
remember that bladder cancer is often a chronic disease. 
The high incidence and long survival lead to a high prevalence of the disease. Lifelong 
routine monitoring and treatment are often necessary. The cost in bladder cancer, from 
diagnosis to death, is the highest of all cancers per patient. Only a few studies have 
focused on the economic aspects in this disease (Botteman 2003).  
In one Swedish hospital the total cost for bladder cancer diagnosis, treatment and follow-
up was nearly 7,000,000 SEK (2,800,000 SEK per 100,000 inhibitants per year) (Hedelin 
2002). A number of authors have suggested a reduction in the number of cystoscopies 
among patients with low-grade bladder tumours. Follow-up cystoscopies only account for 
13% of the total treatment costs. Thus, a reduction in cystoscopy controls would probably 
only lead to small financial savings. Radical cystectomies account for 34% of the total 
treatment costs, but there are few authors who have studied the economics of the 
procedure. Transurethral resections account for 40% of the total treatment costs (Hedelin 
2002).The overall costs increase when a TURB is performed with the patient staying 
overnight in hospital (Hedelin 2002). Considerable economic gains are possible when 
small-sized tumours are treated under local anaesthesia at the time of the follow-up 
cystoscopy. 
Follow-up – Bladder cancer 
Even though all treatments for bladder cancer including TURB, endovesical 
chemotherapy, immunotherapy and cystectomy decrease the recurrence and progression 
rate, the persistent possibility of developing new tumours obliges the urologist to perform 
life-long follow-up. Follow-up consists of regular check-up cystoscopies. After every 
recurrence, the cystoscopy schedule restarts from the beginning. 
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Follow-up Ta grade 1, low-grade tumours  
Stage Ta low-grade tumour is a benign kind of tumour. It has a low risk of progression 
and the recommended follow-up schedule is cystoscopy every 3 months during the first 
two years, every 6 months for another 1-2 years, followed by yearly controls. 
Retrospective studies show that patients with grade 1 tumours who are tumour-free at the 
first follow-up cystoscopy after TURB have few recurrences and progression is very 
uncommon (Fitzpatrick 1986, Parmar 1989, Morris 1993, Öge 2000). A number of 
authors have suggested a less intense follow-up regimen for patients with grade 1 tumours 
and the European Association of Urology recommends cystoscopy at month 9 and 21 for 
patients who are tumour-free at month 3 (Parmar 1989, Morgan 1991, Abel 1993, Morris 
1993, Gulliford 1994, Hall 1994, Olsen 1995, Öge 2000, EAU Guidelines 2007). Follow-
up cystoscopy should continue for at least 5 years. Still, many urologists control patients 
at the traditional intervals, which are the same for all bladder tumours, regardless of 
grade. 
Follow-up Ta grade 2-3 – high-grade tumours 
Cystoscopy is recommended every 3 months for the first 2 years, every 6 months for 
another 1-2 years followed by yearly controls lifelong. Patients with grade 3 tumours 
should receive adjuvant intravesical BCG treatment. Treatment of patients with grade 2 
tumours is controversial. Most patients with grade 2 according to the 1973 WHO 
classification system have a low risk of progression and need no adjuvant therapy but the 
situation is quite different for patients with WHO 1999 grade 2 tumours. Such patients 
have high-grade tumours with a significant risk of progression and intravesical BCG 
seems logical. There are, however, no instillation studies which focus on patients with 
grade 2 WHO 1999 and the possible benefit of such adjuvant treatment is simply not 
studied. 
Follow-up T 1 grade 1-3 and CIS 
The prevailing opinion is that patients with stage Ta/T1/Tis grade 3 tumours should 
undergo a second resection to improve the number of tumour-free patients and obtain a 
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correct staging. An alternative to a second resection is as follows: Intravesical treatment 
2-3 weeks after TURB. Follow-up cystoscopy 4-6 weeks after the last intravesical 
treatment. If a recurrence is seen it will be treated with TUR. Patients who have low-grade 
recurrences may be treated with more instillations. Radical cystectomy is recommended 
in case of a new invasive grade 3 tumour or recurrent CIS.
Follow-up after curative cystectomy 
It seems appropriate with a physical examination about 2-3 months  postoperatively. It 
may include a chest x-ray, urine analysis, sonography of liver, kidney and 
retroperitoneum. The follow-up is supposed to find disturbances in kidney function, 
urinary infection, reservoir stones, strictures or urothelial tumours in the upper urinary 
tract or urethra.
Cytology and cystoscopy are recommended in case of a retained urethra.  
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Aims of the study 
Paper I 
To determine the costs for a cystectomy, with and without complications and to study 
prognostic factors related to the total costs.  
Paper II 
To investigate the results of the intravenous pyelography which usually is performed 7-14 
days after cystectomy.   
Paper III 
To study if a single instillation of epirubicin after transurethral resection may influence 
the time to the first recurrence and its size. 
Paper IV 
To study if a routine with reduced numbers of follow-up cystoscopies during the first two 
years in patients with low-grade stage Ta tumour is medically safe and clinically feasible. 
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Patients and methods 
Paper I 
We studied the clinical records and relevant economy files for 70 consecutive patients 
subjected to radical cystectomy between March 1994 and April 1998 in Sahlgrenska 
University Hospital. Twenty-two different variables were recorded for each patient. The 
total costs and costs for various services for each patient were retrieved in the records of 
the hospital administration. The itemised costs for “Room and board” were calculated 
each year based on actual costs for the urology department during the preceding year. 
Costs were included for all employees and for emergency service as well as for the 
hospital administration. The cost per day is thus an average cost for urology patients and 
not the true cost for a patient treated with cystectomy. All prices were corrected for 
inflation according to the health care consumer price index.  
An uncomplicated case was arbitrarily defined as a patient with at most 2 days in the 
intensive care unit and no reoperation.  
We have calculated mean, standard deviation, median and range with the StatView 
statistical computer program. For comparison between groups, Mann-Whitney´s U-test 
was used for ordered and continuous variables, and Fisher´s exact test for dichotomous 
variables. Spearman´s non-parametric correlation coefficient was used in all correlation 
analyses. Partial correlation analyses and logistic regression was used in order to evaluate 
if a variable (with significant relationship to cost) directly or indirectly affected cost, 
given another variable (covariate). Stepwise regression analysis was used after 
transforming the dependent variable to normal distribution by calculating normal score 
using Blom´s method (Blom 1958). All tests were two-tailed and conducted at 5% 
significance level. Statistician Gunnar Ekeroth performed the statistical analyses of the 
study. 
32
- 33 - 
Paper II 
We identified a total number of 200 consecutive patients who were treated with radical 
cystectomy and urinary diversion between 1994 and 2002. The complete clinical records 
of all 200 patients were available in the archives of the hospital. The data concerning the 
postoperative period were scrutinized. We registered date of surgery, type of diversion, 
symptoms or signs of urinary leakage or obstruction and date and results of all 
postoperative radiological examinations. 178 patients were finally evaluated and we 
registered the frequency of significant findings at routine postoperative urography.  
Paper III 
A total number of 404 patients in 13 hospitals were randomised to either one instillation 
of 50 mg epirubicin or placebo within 6 hours after TUR of bladder tumours.  
It was estimated that 60% of the patients in the epirubicin group and 40% of  the patients 
in the placebo group were free of recurrences after 2 years. A minimum number of  
130 patients in each arm were required when calculating with a power of 0.9 with a 
statistical significance of 5%. Inclusion criteria were 1-3 papillary tumours, a maximal 
tumour diameter of 30 mm and a tumour which looked like a grade 1-2 tumour. The 
randomisation was done by study nurses at each participating centre from lists with pre-
determined treatment alternatives which were generated at random by a statistician. There 
were separate lists for patients with primary and recurrent tumours. Patients were 
randomly allocated to receive either 50 mg epirubicin in 50 ml saline or 50 ml saline 
which was instilled within 6 hours after TUR. Patients were evaluated with cystoscopy 
according to the routines at each participating centre and follow-up was terminated  
24 months after inclusion. 
We calculated the costs of a single instillation when the study started in 1998. All costs 
have been updated to the year 2006 using the consumer price index for the health and care 
sector (www.scb.se) and transformed from SEK to USD using an exchange rate of  
6.65 SEK=1 USD. It was assumed that a nurse would have to spend an average of  
45 minutes with the procedure. This included time to go to the pharmacy, time to go to the 
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recovery room, instillation and finally disposal of the toxic solution (54 USD). The 
epirubicin solution costs amounted to 210 USD and the total cost for one patient is 264 
USD. The total cost for all 203 patients in the epirubicin group was 53,592 USD. 
Calculation of costs for operative procedures in Sahlgrenska University Hospital were 
performed in 1997. These data show that the cost of  a TUR for bladder cancer with a 
hospitalised patient is 4,210 USD and a TUR in day surgery with the patient under spinal 
or general anaesthesia is 758 USD. A biopsy and fulguration under local anaesthesia at 
the time of follow-up cystoscopy amounted to 587 USD. For the purpose of this study, we 
assumed that costs in the other 13 hospitals were the same as in Sahlgrenska University 
Hospital.  
The Mann-Whitney U-test was performed to test the difference between treatment groups 
for continuous variables and Fisher´s exact test for dichotomous variables. The log-rank 
test was performed to test differences in survival functions between the two treatment 
groups. For descriptive purposes Kaplan-Meier estimates were presented. All tests were 
two-tailed and conducted at 5% significance level. 
Statistician Anders Odlén, Gunnar Ekeroth and Aldina Pivodic, performed the statistical 
analyses of the study.  
Paper IV 
Patients who were tumour-free at the first follow-up cystoscopy 4 months after TUR of a 
low-grade tumour (pTaG1, WHO 1999) had their next cystoscopies at month 12 and 
month 24 omitting controls at months 8, 16 and 20. The clinical records were scrutinised 
in order to avoid inclusion of patients with earlier high-grade or invasive tumours. All 
urologists were given oral and written information about this new follow-up routine.  
Patients with stage Ta grade 2 tumours (WHO 1973) were also included if a 
histopathological review, some weeks later, showed a grade 1 (WHO 1999) tumour. The 
size of the tumour was determined by the urologist using an object with a known diameter 
such as the electrode, biopsy forceps or resection-loop for comparison. We registered the 
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date and results of the cystoscopy as well as the size of the recurrences and the way they 
were managed. 
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Results 
Paper I 
The total costs (median) of 53 uncomplicated and 17 complicated cystectomies were 
181,096 SEK and 290,625 SEK, respectively. Room and Board was the most expensive 
single item and accounted for 33-36% of total costs in both groups. The preoperative 
variables had no or minimal prognostic significance for high total costs. The univariate 
analyses show only that (low) age is significantly related (p<0.05) to high total costs in 
the multivariate analysis. High peroperative blood loss was the most important factor 
associated with high total hospital costs for radical cystectomy. 
Paper II 
An intravenous urography was performed in 170 patients and bilateral retrograde 
pyelographies were performed in seven patients. One patient who had bilateral 
pyelostomies underwent an antegrade examination.  
There was no leak identified in anyone out of 170 patients examined by urography. One 
patient with a Bricker conduit had a small leakage at the uretero-intestinal anastomosis 
diagnosed by a retrograde examination. 
Paper III 
Seventy-nine (51.0%) out of 155 evaluable patients in the epirubicin group had a 
recurrence as compared to 95 (62.5%) out of 152 patients in the placebo group (p=0.04). 
Most recurrences (63.3%) were small-sized (1-5 mm). The tumour size was unknown in  
5 patients. Thirty-three (42.9%) out of 79 patients with recurrences in the epirubicin arm 
compared to 29 patients (31.5%) out of 95 in the placebo arm had larger (>5 mm) first 
recurrences (p=0.12). Roughly half of the patients with first recurrences were managed in 
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day surgery and the other half spent a total number of 145 days in hospital, with no 
difference between groups.  
Paper IV 
A total number of 196 patients were notified by the urologists in our institution and 
registered between June 2000 and June 2006. A total number of 138 patients were found 
to fulfill the inclusion criteria. Fifty-eight patients were not accepted for inclusion by the 
study coordinator for inclusion for the following reasons:  The first cystoscopy was not 
performed at 4 months +/- 2 weeks, previous high-grade or invasive tumour or no tumour 
at all. Eighty-seven of 138 patients were examined at month 12 +/- 1 month.  At month 
12, 28 patients had recurrences and 59 had not. The recurrences were solitary in  
21 patients and multiple in 7 patients. Twenty-four out of 28 recurrences (86%) were 
fulgurated with or without biopsy under local anaesthesia at the 12-month control and  
4 patients (14%) were treated under general or spinal anaesthesia. Fifty-one other patients 
were examined more than one month before or after the 12-month date. During the first 
year only a few of these patients had recurrences consisting of small tumours which were 
fulgurated under local anaesthesia at the time of the follow-up cystoscopy. No tumour 
progression was registered.  
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Discussion 
Paper I 
 It is obvious that there is much money to save if most of the complications after 
cystectomy could be avoided. Our study could not show that it is possible to predict who 
will develop complications among those patients selected for operation. We have only 
found one paper where cystectomy costs were determined and the greatest difference in 
costs was increasing costs for laboratory and pharmacy costs, which are 4-12 times higher 
today. 
The duration of hospital stay has been reported to be from 21.5 days in Boston in  
1969-1973 to 7 days in Nashville between 1995 and 2000. Complications are seen in  
20-30% after radical cystectomy, even in institutions where many operations are 
performed each year. The definition of a complication varies from author to author but the 
high percentage can be explained by a complicated operation in a patient group with a 
high prevalence of cardiovascular and respiratory disease. The major finding in our study 
was that a high number of blood transfusions were associated with high total costs for 
cystectomy. Jahnson and associates studied the extent of blood transfusion and cancer-
related mortality in a cohort of 130 patients treated with cystectomy. No overall 
association between extent of blood transfusion and cancer-related mortality was found 
but a tendency towards an increased risk early in the follow-up period was observed 
(Jahnson 1994). 
The Nashville group reported that the mean blood loss was as low as 523 ml when a 
stapler device was used and 756 ml when the traditional technique was used. The data 
from Nashville regarding operating time, bleeding and hospital stay are impressive. 
Chang and associates adhere to a collaborative clinical care pathway for radical 
cystectomy and the surgeons each perform more than 30 cystectomies every year (Chang 
2002).  
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Paper II 
 All patients who had signs and symptoms of urinary leakage or obstruction were 
identified before the time of the planned urography. This is the main explanation why we 
did not find one single patient with urine leak or stricture out of 170 examined by 
urography. It is unlikely that there is a leakage of clinical importance if there is no urine 
in the abdominal drains. We presume that it is of limited benefit to diagnose a leakage 
early if there is no urine in the drains and no signs or symptoms. The results after 
stentograms 5-8 days postoperatively in 73 patients were reported by Manion, who 
identified 3 ureteral leaks in 135 ureteroenteric anastomoses (Manion 1997). In another 
study the incidence of leaks and complications 13 days postoperatively in 51 patients who 
underwent routine stentograms was reported. They concluded that routine evaluation of 
the ureterointestinal anastomosis with stentograms before stent removal was unnecessary 
and may increase patient morbidity (Pantuck 1997). Both authors concluded that routine 
evaluation was unnecessary and Pantuck even suggested that it may increase patient 
morbidity. Pantuck and associates estimated the additional cost of detecting a single 
anastomotic leakage with routine stentograms to 58,000 USD in 1997. The cost in March 
2004 for a urography in our radiology department is approximately 290 USD. The total 
cost for 170 patients amounts to 49,300 USD, which does not include transportation 
services for patients. 
Paper III 
Sylvester and associates performed a meta-analysis using 7 published studies and 
demonstrated a significant benefit of a single instillation over placebo (Sylvester 2004). 
The net benefit was estimated to be 12% or, in other words, the number of patients needed 
to treat to prevent one recurrence is 8.5. One should keep in mind that these calculations 
were based on the evaluable number of patients in the studies included in the meta-
analysis. There was a high percentage of excluded patients in most studies since the 
randomisation procedure was performed before the true nature of the tumour was known. 
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As many as up to 28% of the patients in the larger studies were excluded mainly because 
the histopathological report demonstrated no tumour or a muscle-invasive tumour. In 
other words, in clinical practice, the number of patients needed to treat in order to prevent 
one recurrence is reasonably higher than 8.5 since patients cannot be excluded as they can 
in a study. The authors of single instillation studies did not report the size of the first 
recurrences (Burnand 1976, Abrams 1981, Zincke 1983, Oosterlinck 1993, Bouffioux 
1995, Tolley, Ali-El-Dein 1997, Rajala 2002, Okamura 2002). One exception is Solsona 
et al. who stated that “early recurrences comprised in general a few small papillary 
tumours.” Unfortunately, exact data on the recurrence size cannot be found in their paper. 
The reason is that they categorised recurrences which were 1-9mm, as 1cm tumours. The 
resulting size range of the recurrences is 1-2 cm which, of course, is unintentionally very 
misleading. 
A watchful waiting policy in small recurrent tumours was recently suggested by Soloway 
et al. Gofrit et al. studied recurrent TaG1 tumours and found a watchful waiting policy 
quite acceptable, in particular in patients with tumours less than 5 mm in diameter since 
their average monthly growth was much smaller than larger tumours (Gofrit 2006, 
Soloway 2003). 
 Most likely, almost all recurrences in the present study ought to have been possible to 
treat under either local anaesthesia or under full anaesthesia as a day-surgery procedure. If 
so, a single instillation policy would result in increased costs for the health care system.  
One weakness with the present study is that the tumour size was estimated by the surgeon 
and not determined in a precise way. We believe that this should not have influenced the 
result of the study due to the high number of patients and since it was randomised. One 
might argue that another weakness was the short follow-up period. 
Paper IV 
The clinical message of our study is that patients with a negative cystoscopy at month 4 
after TUR of a grade 1 tumour have a benign course of disease. 
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There are data that suggest that 40% of all costs for treatment of bladder cancer are 
attributable to TUR and only 13% to follow-up cystoscopies (Hedelin 2002). 
Consequently, the potential savings by treating small-sized recurrences under local 
anaesthesia are of course much higher than the savings from omittance of some 
cystoscopies.  
Our results show that the new routine is safe or, in other words, patients with pTaG1 and a 
negative first cystoscopy are a selected group with extremely low risk of progression in 
stage. Outpatient treatment of low-grade recurrences has been done for more than 
50 years at a cost which is only 10-20% of that for inpatient management (Klein 1981, 
Hedelin 2002). It can be assumed that fulguration under local anaesthesia is better 
tolerated using a flexible cystoscope and many authors have shown the feasibility and 
safety using such an instrument (German 1992, Wedderburn 1999). 
A high proportion of small-sized lesions in patients with a history of bladder cancer are 
actually histologically non-malignant  (Svatek 2005). It would have been an advantage in 
the present study if all tumours were biopsied. Patients with non-malignant changes could 
consequently have had their next follow-up visit after 12 months and not after 4 months, 
which would result in a lower percentage with recurrences at the 12-month visit.  
A weakness with our study is that there were a high number of patients who did not 
follow the routines. These patients also had small-sized recurrences and no serious 
tumours. The timing of the first cystoscopy may also be questioned since it was 
performed at 4 months according to local routines. Intuitively, a negative first cystoscopy 
at 4 months must be a stronger sign of good prognosis than a negative cystoscopy at 
3 months. It may, in our opinion, be a good idea to separate “good” grade 1 tumours from 
“bad” grade 2-3 tumours and have separate “tracks” with an initial 4-month cystoscopy 
for patients with grade 1 tumours and 3-month cystoscopy for patients with high-grade 
tumours (grade 2 and 3). Based on our experience we suggest that one interested urologist 
aided by a secretary is given the possibility to supervise the changing of follow-up 
routines in order to ensure that all patients who should follow the new routine also do it. 
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CONCLUSIONS 
Paper I 
Total costs may be very high for a cystectomy with complications. The peroperative 
blood loss was the most important factor associated with high total hospital costs for 
radical cystectomy due to bladder cancer. The bleeding can be influenced why substantial 
reductions in total costs for cystectomy seem possible. 
  
Paper II 
A routine postoperative urography is not necessary in patients who have a normal 
postoperative course after cystectomy and urinary diversion. 
Paper III 
We confirmed the results of previous studies which showed that 8.5 patients have to be 
treated with a single instillation to prevent one recurrence. Furthermore, our data may 
indicate that only small-sized recurrences are prevented such that could easily be 
fulgurated under local anaesthesia at the time of follow-up cystoscopy. The benefit of 
single instillations can be questioned if this finding can be confirmed by others. 
Paper IV 
Patients with low-grade stage Ta tumours who are tumour-free at 4 months can safely 
follow a routine with cystoscopy at month 12 and 24. One should be aware of the risk that 
true high-grade tumours are erroneously included and followed at too infrequent intervals.  
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Swedish summary 
Syfte: Att fastställa kostnader för cystektomi och studera prognostiska faktorer relaterade 
till totalkostnaden. Att studera resultaten av de radiologiska undersökningarna som 
rutinmässigt utförs 7-14 dagar efter cystektomi. Att studera om en singeldos epirubicin 
efter transurethral resektion av en blåstumör påverkar tid till recidiv och storlek på det 
första recidivet. Att prospektivt studera om ett reducerat antal cystoskopikontroller hos 
patienter med låggradig blåstumör är kliniskt genomförbart.  
Patienter och metoder: Journaler och relevanta ekonomiuppgifter för 70 patienter 
analyserades. Kostnader beräknades för varje cystektomi och olika faktorer som var 
relaterade till totalkostnaden analyserades. Resultatet av urografin studerades för  
200 konsekutiva patienter som genomgått cystektomi. Totalt randomiserades  
404 patienter på 13 sjukhus till endera 50 mg epirubicin eller placebo inom 6 timmar 
efter TUR av blåstumör.  
Patienter med låggradig, Ta tumör utan recidiv vid första cystoskopikontrollen vid 
fyra månader(±2veckor) blev kontrollcystoskoperade vid 12 månader(±1 månad) 
och därnäst vid 24 månader(±2 månad). 
Resultat: Mediankostnaden för en cystektomi var 189.479 SEK. Kostnad för vård 
på avdelningen var den enskilt dyraste posten. Blodförlusten under operation 
var den mest betydelsefulla faktorn associerad till totalkostnad. Ingen patient av de 
170 som genomgick en postoperativ urografi hade urinläckage eller striktur. 
Således är denna undersökning onödig så länge det postoperativa förloppet är 
normalt. Sjuttionio (51%) av 155 evaluerbara patienter i epirubicinarmen fick 
recidiv jämfört med 95 (62.5%) av 152 i placebo gruppen (p=0.04). De flesta 
recidiven (63.3%) var små (1-5mm). 33 (42.9%) av 79 patienter med recidiv i 
epirubicinarmen jämfört med 29 patienter (31.5%) av 95 i placeboarmen hade 
större(>5 mm) första recidiv.  Resultat från tidigare studier konfirmerades, vilket 
visar att 8.5 patienter behöver behandlas med en singelinstillation för att förhindra 
ett recidiv. Vidare talar våra data för att det bara är små recidiv som förhindras, 
sådana som kirurgiskt enkelt kan åtgärdas på mottagningen i lokal anestesi i 
samband med uppföljningscystoskopin. Nyttan med engångsinstillation kan 
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ifrågasättas om våra fynd kan konfirmeras av andra.
Patienter med låggradig Ta tumör som är tumörfria vid 4-månaderskontrollen kan 
på ett säkert sätt vidare kontrolleras månad 12 och 24. 
44
- 45 - 
ACKNOWLEDGEMENTS 
I want to express my sincere gratitude to: 
Sten Holmäng, my scientific and surgical tutor and friend, for never-ending energetic 
guidance and invaluable support with everything throughout the work with this thesis and 
all other things. Sten, you indeed possess an enormous body of knowledge in the field of 
bladder cancer and, moreover, although I really feel that I am surrounded by most reliable 
colleagues, no one compares to you! Perhaps you will also find it a little astonishing as 
well as amusing that I also think that you are a very handsome man. 
Hans Hedelin, my cotutor for adding quality to the project and once having introduced 
me in to the field of bladder cancer. 
  
Pär Lodding, Head of the Department of Urology, Sahlgrenska University Hospital for 
creating a good working climate for me during this project. 
Jan-Erik Damber, Head of the Department of Urology, the Sahlgrenska Academy, for 
providing a good academic climate. 
Ralph Peeker, my friend and clinical tutor, for all crazy things you make me do and your 
artistic attitude to everything. That makes life bright!  
  
Sven Lundstam, for quick and always valuable critics and for making things easier for 
everyone to understand. 
Elisabeth Ståhlgren, Helén Ahlgren, Mia Ahlbom and Gunilla Paulinder for excellent 
secretarial assistance with everything I asked for and even a bit more. Thank you girls! 
My dear colleagues Ýr Logadottír and Magnus Fall for all support. 
45
- 46 - 
Ali Khatami for all fun during all late evenings and for all your willingness to provide 
excellent technical support when my computer and I failed to go along with each other. 
Silas Pettersson and Lars Grenabo, former Heads at the Department of Urology, when I 
once begun. 
Solvikingarna for keeping me in good condition and in a good mood during my work 
with this thesis. 
This work was supported by grants from Göteborg Medical Society, Märtha and Gustaf 
Ågren´s research foundation, Odd Fellow Logen Gustaf Adolf and Pfizer. 
46
- 47 - 
References 
Abel PD. Follow-up of patients with "superficial" transitional cell carcinoma of the 
bladder: the case for a change in policy. Br J Urol 1993; Aug; 72(2):135-42. 
Abrams PH, Choa RG, Gaches CGC, Ashken MH, Green NA. A controlled trial of  single 
dose intravesical Adriamycin in superficial bladder tumours. Br J Urol 1981;53:585- 587. 
  
Ali-El-Dein A, Nabeeh A, El-Baz M, Shamaa S, Ashamallah A. Single-dose versus 
multiple instillations of epirubicin as prophylaxis for recurrence after transurethral 
resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized 
controlled study. Br J Urol 1997;79:731-5.  
American Cancer Society Inc, 2007. www.cancer.org 
Andius P. Carcinoma of the urinary bladder. Göteborg Universitet, 2006 
Bergkvist A, Moberger G. Classification of bladder tumors based on the cellular pattern. 
Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-
up of eight years. Acta Chir Scand 1965, Oct 130(4):371-8 
Blom G. Statistical Estimates and Transformed Beta Variables, New York: John Wiley & 
Sons, Inc. 1958 
Boman H. Bladder cancer: Urine tumour markers and Hematuria. Thesis, Göteborg 
Universitet  2002. 
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of 
bladder cancer. Pharmacoeconomics 2003; 21: 1315-1330. 
47
- 48 - 
Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Boekken Krueger C, de Pauw M, et al. 
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: 
results of 2 European Organization for research and treatment of cancer randomized trials 
with mitomycin C and doxorubicin comparing early versus delayed instillations and short-
term versus long-term treatment. J Urol 1995;153:934-41.  
 Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED, Lloyd-Davies RW. Single dose 
intravesical Thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell 
bladder carcinoma. Br J Urol 1976;48:55-9.  
Busch C and Algaba F. The WHO/ISUP 1998 and WHO 1999 system for malignancy 
grading of bladder cancer. Scientific foundation and translation to one another and 
previous system. Virchows Arch 2002, 441:105-108. 
Bredin HC, Prout Jr GR. One-stage radical cystectomy for bladder carcinoma: operative 
mortality, cost/benefit analysis. J Urol 1977; 117: 447-451. 
Chang SS, Cookson M, Baumgartner RG, Wells N, Smith JA. Analysis of early 
complications after radical cystectomy: results of a collaborative care pathway. J Urol 
2002; 167: 2012-16. 
Chang SS, Baumgartner RG, Wells N, Cookson MS, Smith Jr, JA. Causes of increased 
hospital stay after radical cystectomy in a clinical pathway setting. J Urol 2002; 167: 208-
211. 
Chang SS, Cookson MS, Hassan JM., Wells N, Smith Jr, JA. Routine postoperative 
intensive care monitoring is not necessary after radical cystectomy. J Urol 2002; 167: 
1321-1324. 
48
- 49 - 
Chang SS, Smith Jr, JA, Cookson MS. Decreasing blood loss in patients treated with 
radical cystectomy: a prospective randomized trial using a new stapling device. J Urol 
2002; 169: 951-954. 
Cookson M. Long-term effects of BCG: Impact on disease progression. Supplement to 
Renal & Urology News, October 2004. 
European Association of Urology Guidelines 2007 
Fitzpatrick JM, West AB, Butler M, Lane V, O´Flynn JD. Superficial bladder tumors 
(stage pTa, grades 1 and 2): the importance of recurrence pattern following initial 
resection. J Urol 1986;135:920-22. 
German K, Hasan ST, Derry C. Cystodiathermy under local anaesthesia using the flexible 
cystoscope. Br J Urol 1992;69:518-20. 
Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent 
TAG1 bladder tumors. Eur Urol 2006;49:303-7.  
Gulliford M, Burney PGJ, Petruckevitch A. Can efficiency of follow-up for superficial 
bladder cancer be increased? Annals of the Royal College of Surgeons of England 
1993;75:57-61. 
49
Hall RR, Parmar MKB, Richards AB, Smith PH. Proposal for changes in cystoscopic 
follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 
1994;308:257-60. 
- 50 - 
Hedelin H, Holmäng S, Wiman L. The cost of Bladder Toumour Treatment and 
Follow-up. Scand J Urol Nefrol 2002;36:344-347 
Holmäng S, Hedelin H, Anderström C, Holmberg E, Busch C, Johansson SL. Recurrence 
and progression in low grade papillary urothelial tumors. J Urol. 1999 Sep;162:702-7. 
Holmäng S. Follow-Up of patients With Noninvasive and Superficial Invasive Bladder 
Cancer. Seminars in Urologic Oncology,   2000; 18: 273-279. 
Jahnson S, Bergström R, Pedersen J. Extent of blood transfusion and cancer-related 
mortality after cystectomy and urinary diversion for bladder cancer. Br J Urol 1994; 74: 
779-784. 
Klein FA, Whitmore WF, Jr. Bladder papilloma: therapeutic and cost effect of outpatient 
department management. Urology 1981;18:247-9. 
Larsson P, Wijkström H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, Onelöv E, 
and Steineck G. A population-based study of 538 patients with newly detected urinary 
bladder neoplasms followed during 5 years.Scand J Urol Nephrol 2003;37(3):195-201 
Malavaud B, Vaessen, Mouzin M, Rischmann P, Sarramon JP, Schulman C. 
Complications for radical cystectomy. Eur Urol 2002; 39: 79-84. 
Malmström P-U. Intravesical therapy of superficial bladder cancer. Oncology 
Hemathology 47, 2003, 109-126. 
50
- 51 - 
Malmström PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder 
cancer. A retrospective analyses of 232 patients with greater than or equal to 5-year 
follow-up. Scand J Urol Nephrol 1987;21:185 
Malmström P-U. Urinblåsecancer in Urologi, eds: Damber JE and Peeker R. Student 
litteratur, 2006. 
Manion SP, Bedford Waters W, Flanigan RC. Efficacy of retrograde stentograms 
following cystectomy and diversion. J Urol 1997; 158: 776-7. 
McDougal WS. Use of intestinal segments and urinary diversion. In Campbell´s Urology, 
eight edition. Saunders, Philadelphia 2002. 
Morgan JDT, Bowsher W, Griffiths DFR, Matthews PN. Rationalisation of follow-up in 
patients with non-invasive bladder tumours. A preliminary report. Br J Urol 1991;67:158-
61. 
Morris SB, Shearer RJ, Gordon EM, Woodhouse CRJ. Superficial bladder cancer: Timing 
of check cystoscopies in the first year. Br J Urol 1993;72:446-448. 
Murphy WM. The term 'superficial bladder cancer' should be abandoned. Eur Urol 
2000;38:597-599.
Napalkov P, Maisonneuve P, Boyle P. Epidemiology of bladder cancer. In Superficial 
Bladder Cancer edited by Pagano F and Fair W, ISIS Medical Media 1997. 
Nationellt kvalitetsregister för blåscancer, rapport för diagnosår 2005. Socialstyrelsen, 
Svensk urologisk förening, Sveriges Onkologiska Centra. Regionala Tumörregistret, 
Universitetssjukhuset i Lund. 
51
- 52 - 
Okamura K, Ono Y, Kinukawa T, Matuura O, Yamada S, Ando T, et al. Randomized 
study of single early instillation of (2´´R)-4´-0-Tetrahydropyranyl-doxorubicin for a 
single superficial bladder carcinoma. Cancer 2002;94:2363-8.  
Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a 
randomized controlled trial. Scand J Urol Nephrol 1995; suppl 172, 33-36. 
Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R, et al. A 
prospective European organization for research and treatment of Cancer Genitourinary 14 
Group randomized trial comparing transurethral resection followed by a single 
intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma 
of the bladder. J Urol 1993;149:749-52. 
Paik ML, Limitations of computerized tomography in staging invasive bladder cancer 
before radical cystectomy. J Urol 2000;163(6):1693-6. 
Pantuck AJ, Weiss RE, Cummings KB. Routine stentograms are not necessary before 
stent removal following radical cystectomy. J Urol 1997; 158: 772-5. 
Parmar MKB, Freedam LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence 
and followup policies in the treatment of superficial bladder cancer: report from the 
British Medical Research Council subgroup on superficial bladder cancer (Urological 
cancer working party). J Urol 1989;142:284-8. 
Popart RJM, Goodall J, Coptcoat MJ, Thompson PM, Parmar MKB, Masters JRW, 
Superficial bladder cancer: the response of a marker tumour to a single intravesical 
instillation of epirubicin. Br J Urol 1994;74:195-9.
52
- 53 - 
Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E and the Finnbladder group. 
Perioperative single dose instillation of epirubicin or interferon-alfa after transurethral 
resection for the prophylaxis of primary superficial bladder cancer recurrence: a 
prospective randomized multicenter study- Finnbladder III long-term results. J Urol 2002; 
168:981-5. 
Rosario DJ, Becker M, Andersson JB. The changing pattern of mortality and morbidity 
from radical cystectomy. Br J Urol 2000; 85: 427-430. 
Schoenberg M, Management of invasive and metastatic bladder cancer. In Campbell´s 
Urology, eighth edition. Saunders, Philadelphia 2002. 
Socialstyrelsen: Epidemiologiskt centrum, www.socialstyrelsen.se
Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive 
papillary bladder tumors. J Urol 2003;170:438-41. 
Soloway MS. It is Time to Abandon the "Superficial" in Bladder Cancer. Eur Urol 2007, 
article in press. 
Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a 
single immediate mitomycin C instillation in patients with low risk superficial bladder 
cancer: short and long-term followup. J Urol 1999;161: 1120-23. 
Statistiska Centralbyrån, Statistics Sweden, 2003,  www.scb.se  
Steineck, G, Norsell SE and Feychting M Diet, tobacco and urothelial cancer. A 14-year 
follow-up of 16,477 subjects. Acta Oncologica 1988;27:323-327. 
Sylvester RJ, Oosterlinck W, van der Meijden A. A single immediate postoperative 
instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 
53
- 54 - 
bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 
2004;171:2186-90.  
Tolley DA, Parmar MKB, Grigor KM, Lallemand G, and the Medical Research  
Council Superficial Bladder Cancer Working Party. The effect of intravesical  
mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further 
report with 7 years of followup. J Urol 1996;155:1233-8. 
Wedderburn AW, Ratan P, Birch BR. A prospective trial of flexible cystodiathermy for 
recurrent transitional cell carcinoma of the bladder. J Urol 1999;161:812-4. 
Wijkström H. Diagnosis of Transitional cell Bladder Carcinoma. A study of current 
classification and some additional diagnostic methods. Thesis, Stockholm, 1984. 
Wijkström H, Norming U, Lagerkvist M., Nilsson B, Näslund I., Wiklund P. Evaluation 
of clinical staging before cystectomy in transitional cell bladder carcinoma; a long-term 
follow up of 276 consecutive patients. Br J Urol 1998;81(5):686-91.  
Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of Thiotepa and  
Doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on 
tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 
1983;129:505-509.  
Öge Ö, Erdem E, Atsu N, Sahin A, Özen H. Proposal for changes in cystoscopic follow-
up of patients with low-grade pTa bladder tumor. Eur Urol 2000;37:271-4. 
54
